These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Breast cancer in BRCA1/2 mutation carriers]. Fabian P; Nenutil R Cesk Patol; 2016; 52(4):206-209. PubMed ID: 27869445 [TBL] [Abstract][Full Text] [Related]
23. The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer. Metcalfe KA; Lubinski J; Gronwald J; Huzarski T; McCuaig J; Lynch HT; Karlan B; Foulkes WD; Singer CF; Neuhausen SL; Senter L; Eisen A; Sun P; Narod SA; Clin Genet; 2018 May; 93(5):1063-1068. PubMed ID: 29206279 [TBL] [Abstract][Full Text] [Related]
25. Inherited mutations in Wen WX; Allen J; Lai KN; Mariapun S; Hasan SN; Ng PS; Lee DS; Lee SY; Yoon SY; Lim J; Lau SY; Decker B; Pooley K; Dorling L; Luccarini C; Baynes C; Conroy DM; Harrington P; Simard J; Yip CH; Mohd Taib NA; Ho WK; Antoniou AC; Dunning AM; Easton DF; Teo SH J Med Genet; 2018 Feb; 55(2):97-103. PubMed ID: 28993434 [TBL] [Abstract][Full Text] [Related]
26. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502 [TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients. Cecener G; Sabour Takanlou L; Sabour Takanlou M; Egeli U; Eskiler GG; Aksoy S; Unal U; Tezcan H; Eryilmaz IE; Gokgoz MS; Tunca B; Cubukcu E; Evrensel T; Cetintas S; Tasdelen I Cancer Genet; 2020 Jan; 240():23-32. PubMed ID: 31706072 [TBL] [Abstract][Full Text] [Related]
28. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H; Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383 [TBL] [Abstract][Full Text] [Related]
29. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Hubert A; Mali B; Hamburger T; Rottenberg Y; Uziely B; Peretz T; Kadouri L Fam Cancer; 2009; 8(3):173-7. PubMed ID: 19016350 [TBL] [Abstract][Full Text] [Related]
30. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525 [TBL] [Abstract][Full Text] [Related]
31. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428 [TBL] [Abstract][Full Text] [Related]
32. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study. Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294 [TBL] [Abstract][Full Text] [Related]
33. Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer. Halpern N; Sonnenblick A; Uziely B; Divinsky L; Goldberg Y; Hamburger T; Peretz T; Kadouri L Int J Cancer; 2017 May; 140(9):2145-2149. PubMed ID: 28120435 [TBL] [Abstract][Full Text] [Related]
34. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population. Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829 [TBL] [Abstract][Full Text] [Related]
35. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Narod SA; Lubinski J; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Rosen B; Kim-Sing C; Isaacs C; Domchek S; Sun P; Lancet Oncol; 2006 May; 7(5):402-6. PubMed ID: 16648044 [TBL] [Abstract][Full Text] [Related]
36. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Akdeniz D; van Barele M; Heemskerk-Gerritsen BAM; Steyerberg EW; Hauptmann M; ; van de Beek I; van Engelen K; Wevers MR; Gómez García EB; Ausems MGEM; Berger LPV; van Asperen CJ; Adank MA; Collée MJ; Stommel-Jenner DJ; Jager A; Schmidt MK; Hooning MJ Breast; 2022 Feb; 61():98-107. PubMed ID: 34929424 [TBL] [Abstract][Full Text] [Related]
37. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402 [TBL] [Abstract][Full Text] [Related]
38. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Barwell J; Pangon L; Georgiou A; Kesterton I; Langman C; Arden-Jones A; Bancroft E; Salmon A; Locke I; Kote-Jarai Z; Morris JR; Solomon E; Berg J; Docherty Z; Camplejohn R; Eeles R; Hodgson SV Int J Cancer; 2007 Oct; 121(7):1631-6. PubMed ID: 17582599 [TBL] [Abstract][Full Text] [Related]
39. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309 [TBL] [Abstract][Full Text] [Related]
40. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]